A phase 1/2 trial of Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) in nasopharyngeal carcinoma, run by PT. Prodia Stem Cell Indonesia, active and no longer recruiting.
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer is a phase 1/2 interventional study registered as NCT05261750 by PT. Prodia Stem Cell Indonesia, with 15 participants enrolled, started 2022-04-30 and due to reach its primary completion in 2026-02-28. Interventions recorded: Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) and Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy).
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.